Dextromethorphan Polistirex Patent Expiration

Dextromethorphan Polistirex is used for treating a variety of conditions such as depression, anxiety, and panic disorders. It was first introduced by Rb Health Us Llc in its drug Delsym on Oct 8, 1982. 3 different companies have introduced drugs containing Dextromethorphan Polistirex.


Dextromethorphan Polistirex Patents

Given below is the list of patents protecting Dextromethorphan Polistirex, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Delsym US5980882 Drug-resin complexes stabilized by chelating agents Apr 16, 2017

(Expired)

Rb Hlth



Dextromethorphan Polistirex's Family Patents

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List

Dextromethorphan Polistirex Generic API Manufacturers

Several generic applications have been filed for Dextromethorphan Polistirex. The first generic version for Dextromethorphan Polistirex was by Tris Pharma Inc and was approved on May 25, 2012. And the latest generic version is by Amneal Pharmaceuticals Llc and was approved on Jul 28, 2017.

Given below is the list of companies who have filed for Dextromethorphan Polistirex generic, along with the locations of their manufacturing plants worldwide.